1013101-36-4 | Pf-04691502

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$41.00	$29.00
5mg	95%	in stock	$86.00	$60.00
10mg	95%	in stock	$121.00	$85.00
50mg	95%	in stock	$299.00	$209.00
250mg	95%	in stock	$1,175.00	$822.00

Description

• Catalog Number: AE11315
• Chemical Name: Pf-04691502
• CAS Number: 1013101-36-4
• Molecular Formula: C22H27N5O4
• Molecular Weight: 425.48087999999996
• MDL Number: MFCD18782794
• SMILES: OCCO[C@@H]1CC[C@H](CC1)n1c(=O)c(cc2c1nc(N)nc2C)c1ccc(nc1)OC

Computed Properties

• Complexity: 654
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 6
• XLogP3: 1.6

Upstream Synthesis Route

2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one serves as a valuable intermediate in chemical synthesis, particularly in the creation of specialized organic compounds. This compound can be used as a key building block in the development of novel pharmaceuticals, agrochemicals, and materials. Its structural features and functional groups make it versatile for use in the modification of complex molecules, enabling researchers to fine-tune properties and activities. By incorporating 2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one into synthesis pathways, chemists can access a wide range of derivatives with varied biological and chemical properties, opening up pathways for innovative advancements in the field of chemistry.

Literature

• p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

  European journal of cancer (Oxford, England : 1990) 20160301

• PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.

  Toxicology letters 20130704

• Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.

  Cancer chemotherapy and pharmacology 20120801

• Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.

  ACS medicinal chemistry letters 20111110

• PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

  Molecular cancer therapeutics 20111101